Risk acceptance in multiple sclerosis paciente on natalizumabe treatment

• Grant number: 15/22721-7
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: February 01, 2016
• End date: January 31, 2017
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Denis Bernardi Bichuetti
• Grantee: Carolina Azze Franco
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

In the last decade, new drugs for multiple sclerosis have been tested and approved. Among them is natalizumab, that despite its high efficacy has its use limited by the risk of developing progressive multifocal leukoencephalopathy. By applying, a questionnaire with inclusion of patients diagnosed with relapsing-remitting multiple sclerosis, we aimed to assess how patients assess the risks of treatment with natalizumab and the factors involved in this evaluation.